BLUF is in public beta. Automated sourcing and summaries by the BLUF engine, monitored by our team. Summaries may contain errors — verify important details at the source. Not medical, legal or financial advice. Public beta — automated summaries may contain errors. Full disclaimer
BLUFSOURCED EVENT BRIEFLAST CHANGED Nov 6, 2026, 5:01 PM
DRUGS, DEVICES & RECALLS • UNITED STATES
Hims & Hers reports agreement with Lilly on compounded GLP-1 drugs
2 SOURCES UNITED STATESNEW
NOT MEDICAL ADVICE
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
BLUF
Hims & Hers says it will not compound GLP-1 medications such as Zepbound in the future under an agreement with Lilly, according to MarketWatch. The supplied articles do not provide further details about the agreement.
HOW THIS BRIEF WAS MADE 2 outlets: 2 national. Automated sourcing and summaries by the BLUF engine. Corrections
Why it matters
The agreement may affect Hims & Hers’ offerings of compounded weight-loss drugs and customers seeking those products. The articles provide no details on its scope or effects on access or prices.
What happens next
Hims & Hers is scheduled to report third-quarter results after the market closes Nov. 9, according to Yahoo Finance. The articles do not say whether the company will provide more details on the agreement then.
Whether Hims & Hers provides details about the agreement in its earnings report
Any further information on which products or services are affected